{
  "ticker": "BDX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974204",
  "id": "02974204",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m94w04h307w1.pdf",
  "summary": "### **Appendix 4C \u2013 Quarterly Report Summary (BCAL Diagnostics, June 2025)**  \n\n#### **Key Highlights:**  \n- **Commercial Launch Progress:**  \n  - 107 commercial tests sold in Q1 post-launch.  \n  - BREASTEST plus\u2122 now available in **8 clinics** (33 breast specialists engaged).  \n  - **93 pathology sites** set up for sample collection.  \n  - Signed commercial agreement with **Cancer Care Associates (CCA)** to expand distribution.  \n\n- **Market Expansion:**  \n  - National rollout strategy expanded to include **GPs focused on women\u2019s health**.  \n  - Policy shift in Australia mandating **breast density reporting** (potential tailwind for adoption).  \n\n- **R&D and Financials:**  \n  - **R&D spend:** $1.2M (quarter), $5.2M (year-to-date).  \n  - **Closing cash balance:** **$4.5M** (vs. $5.0M previous quarter).  \n  - **Estimated R&D tax offset:** ~$2.5M ($1.3M received in June).  \n  - **Estimated funding runway:** **2.5 quarters** (based on current burn rate).  \n\n#### **Material Omissions:**  \n- No new capital raising or material debt disclosed.  \n- No significant operational disruptions or deviations from prior guidance.  \n\n**Conclusion:** Focus on commercial traction and cash runway. Policy tailwinds (breast density reporting) and GP expansion may drive future adoption.",
  "usage": {
    "prompt_tokens": 4984,
    "completion_tokens": 316,
    "total_tokens": 5300,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T22:49:41.382068"
}